Alzheimer's Disease
Conditions
Keywords
PU-AD
Brief summary
This is a first in human Phase 1 study in two parts with healthy volunteers receiving a single dose of PU AD in three small cohorts and a multiple ascending dose in two small cohorts.
Detailed description
This is a Phase 1, double-blind trial in two parts. A single ascending dose study in approximately 3 cohorts receiving a single oral dose of PU-AD or placebo and a multiple ascending dose study in 2 cohorts. Each subject in all cohorts will be administered an oral solution of PU AD or placebo under fasting conditions. Each cohort will contain subjects randomized to active treatment or placebo, evaluating safety and tolerance.
Interventions
DRUGPU-AD
3 cohorts receiving a single oral dose of PU-AD at one time.
DRUGPlacebo
3 cohorts receiving a single oral dose of Placebo at one time
Sponsors
Samus Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female (Women of non-child bearing potential) 2. 18 to 60 years of age for part one, \>/= 60 years of age for part two
Exclusion criteria
1. Women of child bearing potential or Female with positive pregnancy test or who is lactating. 2. History or presence of conditions, which in the judgment of the PI, are known to interfere with the absorption distribution, metabolism, or excretion of drugs. 3. History or presence of conditions that may place the subject at increased risk as determined by the PI. 4. Has taken other investigational drugs or participated in any clinical study within 30 days. 5. Any other condition or prior therapy that, in the PI's opinion, would make the subject unsuitable for the study, or unable or unwilling to comply with the study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety and tolerability of single and multiple doses of PU-AD in healthy subjects | Day 1 to Day 3 | Adverse Event (AE) incidence and changes from baseline in clinical laboratory test results. Number and percentage of subjects reporting any treatment emergent AE will be tabulated by system organ class and preferred term for each treatment (coded using Medical Dictionary for Regulatory Activities). Treatment-emergent AEs will be further classified by severity and relationship to treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine the pharmacokinetics (PK) PU-AD in healthy subjects | Day 1 to Day 3 | Collect PK parameters to estimate human exposure,after dose administration for each cohort will be evaluated using a power model for dose proportionality. (Maximum observed concentration (Cmax). |
Countries
United States
Outcome results
None listed